Cargando…

Impact on follow‐up strategies in patients with primary sclerosing cholangitis

BACKGROUND & AIMS: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow‐up strategies in PSC with the hypothesis that regular imaging improves survival. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergquist, Annika, Weismüller, Tobias J., Levy, Cynthia, Rupp, Christian, Joshi, Deepak, Nayagam, Jeremy Shanika, Montano‐Loza, Aldo J., Lytvyak, Ellina, Wunsch, Ewa, Milkiewicz, Piotr, Zenouzi, Roman, Schramm, Christoph, Cazzagon, Nora, Floreani, Annarosa, Liby, Ingalill Friis, Wiestler, Miriam, Wedemeyer, Heiner, Zhou, Taotao, Strassburg, Christian P., Rigopoulou, Eirini, Dalekos, George, Narasimman, Manasa, Verhelst, Xavier, Degroote, Helena, Vesterhus, Mette, Kremer, Andreas E., Bündgens, Bennet, Rorsman, Fredrik, Nilsson, Emma, Jørgensen, Kristin Kaasen, von Seth, Erik, Cornillet Jeannin, Martin, Nyhlin, Nils, Martin, Harry, Kechagias, Stergios, Wiencke, Kristine, Werner, Mårten, Beretta‐Piccoli, Benedetta Terziroli, Marzioni, Marco, Isoniemi, Helena, Arola, Johanna, Wefer, Agnes, Söderling, Jonas, Färkkilä, Martti, Lenzen, Henrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084018/
https://www.ncbi.nlm.nih.gov/pubmed/35535655
http://dx.doi.org/10.1111/liv.15286
_version_ 1785021646966358016
author Bergquist, Annika
Weismüller, Tobias J.
Levy, Cynthia
Rupp, Christian
Joshi, Deepak
Nayagam, Jeremy Shanika
Montano‐Loza, Aldo J.
Lytvyak, Ellina
Wunsch, Ewa
Milkiewicz, Piotr
Zenouzi, Roman
Schramm, Christoph
Cazzagon, Nora
Floreani, Annarosa
Liby, Ingalill Friis
Wiestler, Miriam
Wedemeyer, Heiner
Zhou, Taotao
Strassburg, Christian P.
Rigopoulou, Eirini
Dalekos, George
Narasimman, Manasa
Verhelst, Xavier
Degroote, Helena
Vesterhus, Mette
Kremer, Andreas E.
Bündgens, Bennet
Rorsman, Fredrik
Nilsson, Emma
Jørgensen, Kristin Kaasen
von Seth, Erik
Cornillet Jeannin, Martin
Nyhlin, Nils
Martin, Harry
Kechagias, Stergios
Wiencke, Kristine
Werner, Mårten
Beretta‐Piccoli, Benedetta Terziroli
Marzioni, Marco
Isoniemi, Helena
Arola, Johanna
Wefer, Agnes
Söderling, Jonas
Färkkilä, Martti
Lenzen, Henrike
author_facet Bergquist, Annika
Weismüller, Tobias J.
Levy, Cynthia
Rupp, Christian
Joshi, Deepak
Nayagam, Jeremy Shanika
Montano‐Loza, Aldo J.
Lytvyak, Ellina
Wunsch, Ewa
Milkiewicz, Piotr
Zenouzi, Roman
Schramm, Christoph
Cazzagon, Nora
Floreani, Annarosa
Liby, Ingalill Friis
Wiestler, Miriam
Wedemeyer, Heiner
Zhou, Taotao
Strassburg, Christian P.
Rigopoulou, Eirini
Dalekos, George
Narasimman, Manasa
Verhelst, Xavier
Degroote, Helena
Vesterhus, Mette
Kremer, Andreas E.
Bündgens, Bennet
Rorsman, Fredrik
Nilsson, Emma
Jørgensen, Kristin Kaasen
von Seth, Erik
Cornillet Jeannin, Martin
Nyhlin, Nils
Martin, Harry
Kechagias, Stergios
Wiencke, Kristine
Werner, Mårten
Beretta‐Piccoli, Benedetta Terziroli
Marzioni, Marco
Isoniemi, Helena
Arola, Johanna
Wefer, Agnes
Söderling, Jonas
Färkkilä, Martti
Lenzen, Henrike
author_sort Bergquist, Annika
collection PubMed
description BACKGROUND & AIMS: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow‐up strategies in PSC with the hypothesis that regular imaging improves survival. METHODS: We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow‐up from 1 January 2000, until death or last clinical follow‐up alive. The primary endpoint was all‐cause mortality. RESULTS: A broad variety of different follow‐up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow‐up, was 0.61 (0.47–0.80) for scheduled imaging with and without ERCP; 0.64 (0.48–0.86) for US/MRI and 0.53 (0.37–0.75) for follow‐up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high‐grade dysplasia as a time‐dependent covariate, HR 0.57 (0.44–0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow‐up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed. CONCLUSIONS: Follow‐up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures.
format Online
Article
Text
id pubmed-10084018
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100840182023-04-11 Impact on follow‐up strategies in patients with primary sclerosing cholangitis Bergquist, Annika Weismüller, Tobias J. Levy, Cynthia Rupp, Christian Joshi, Deepak Nayagam, Jeremy Shanika Montano‐Loza, Aldo J. Lytvyak, Ellina Wunsch, Ewa Milkiewicz, Piotr Zenouzi, Roman Schramm, Christoph Cazzagon, Nora Floreani, Annarosa Liby, Ingalill Friis Wiestler, Miriam Wedemeyer, Heiner Zhou, Taotao Strassburg, Christian P. Rigopoulou, Eirini Dalekos, George Narasimman, Manasa Verhelst, Xavier Degroote, Helena Vesterhus, Mette Kremer, Andreas E. Bündgens, Bennet Rorsman, Fredrik Nilsson, Emma Jørgensen, Kristin Kaasen von Seth, Erik Cornillet Jeannin, Martin Nyhlin, Nils Martin, Harry Kechagias, Stergios Wiencke, Kristine Werner, Mårten Beretta‐Piccoli, Benedetta Terziroli Marzioni, Marco Isoniemi, Helena Arola, Johanna Wefer, Agnes Söderling, Jonas Färkkilä, Martti Lenzen, Henrike Liver Int Gut‐liver Axis, Immunology, Immune Mediated and Cholestatic Diseases BACKGROUND & AIMS: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow‐up strategies in PSC with the hypothesis that regular imaging improves survival. METHODS: We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow‐up from 1 January 2000, until death or last clinical follow‐up alive. The primary endpoint was all‐cause mortality. RESULTS: A broad variety of different follow‐up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow‐up, was 0.61 (0.47–0.80) for scheduled imaging with and without ERCP; 0.64 (0.48–0.86) for US/MRI and 0.53 (0.37–0.75) for follow‐up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high‐grade dysplasia as a time‐dependent covariate, HR 0.57 (0.44–0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow‐up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed. CONCLUSIONS: Follow‐up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures. John Wiley and Sons Inc. 2022-05-16 2023-01 /pmc/articles/PMC10084018/ /pubmed/35535655 http://dx.doi.org/10.1111/liv.15286 Text en © 2022 The Authors. Liver International published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Gut‐liver Axis, Immunology, Immune Mediated and Cholestatic Diseases
Bergquist, Annika
Weismüller, Tobias J.
Levy, Cynthia
Rupp, Christian
Joshi, Deepak
Nayagam, Jeremy Shanika
Montano‐Loza, Aldo J.
Lytvyak, Ellina
Wunsch, Ewa
Milkiewicz, Piotr
Zenouzi, Roman
Schramm, Christoph
Cazzagon, Nora
Floreani, Annarosa
Liby, Ingalill Friis
Wiestler, Miriam
Wedemeyer, Heiner
Zhou, Taotao
Strassburg, Christian P.
Rigopoulou, Eirini
Dalekos, George
Narasimman, Manasa
Verhelst, Xavier
Degroote, Helena
Vesterhus, Mette
Kremer, Andreas E.
Bündgens, Bennet
Rorsman, Fredrik
Nilsson, Emma
Jørgensen, Kristin Kaasen
von Seth, Erik
Cornillet Jeannin, Martin
Nyhlin, Nils
Martin, Harry
Kechagias, Stergios
Wiencke, Kristine
Werner, Mårten
Beretta‐Piccoli, Benedetta Terziroli
Marzioni, Marco
Isoniemi, Helena
Arola, Johanna
Wefer, Agnes
Söderling, Jonas
Färkkilä, Martti
Lenzen, Henrike
Impact on follow‐up strategies in patients with primary sclerosing cholangitis
title Impact on follow‐up strategies in patients with primary sclerosing cholangitis
title_full Impact on follow‐up strategies in patients with primary sclerosing cholangitis
title_fullStr Impact on follow‐up strategies in patients with primary sclerosing cholangitis
title_full_unstemmed Impact on follow‐up strategies in patients with primary sclerosing cholangitis
title_short Impact on follow‐up strategies in patients with primary sclerosing cholangitis
title_sort impact on follow‐up strategies in patients with primary sclerosing cholangitis
topic Gut‐liver Axis, Immunology, Immune Mediated and Cholestatic Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084018/
https://www.ncbi.nlm.nih.gov/pubmed/35535655
http://dx.doi.org/10.1111/liv.15286
work_keys_str_mv AT bergquistannika impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT weismullertobiasj impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT levycynthia impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT ruppchristian impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT joshideepak impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT nayagamjeremyshanika impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT montanolozaaldoj impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT lytvyakellina impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT wunschewa impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT milkiewiczpiotr impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT zenouziroman impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT schrammchristoph impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT cazzagonnora impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT floreaniannarosa impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT libyingalillfriis impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT wiestlermiriam impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT wedemeyerheiner impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT zhoutaotao impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT strassburgchristianp impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT rigopouloueirini impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT dalekosgeorge impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT narasimmanmanasa impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT verhelstxavier impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT degrootehelena impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT vesterhusmette impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT kremerandrease impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT bundgensbennet impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT rorsmanfredrik impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT nilssonemma impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT jørgensenkristinkaasen impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT vonsetherik impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT cornilletjeanninmartin impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT nyhlinnils impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT martinharry impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT kechagiasstergios impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT wienckekristine impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT wernermarten impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT berettapiccolibenedettaterziroli impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT marzionimarco impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT isoniemihelena impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT arolajohanna impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT weferagnes impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT soderlingjonas impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT farkkilamartti impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT lenzenhenrike impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis
AT impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis